[Antineoplastic activity of antibiotic 1719 from the group of diazo compounds].
D000284:Administration, Oral; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000627:therapeutic use; D001391:Azo Compounds / Q000008:administration & dosage* / Q000627:therapeutic use; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D005260:Female; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007939:Leukemia L1210 / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D051381:Rats; D012510:Sarcoma 180 / Q000188:drug therapy; D012511:Sarcoma 37 / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy; D013997:Time Factors; D014625:Vaginal Neoplasms / Q000188:drug therapy
D000903:Antibiotics, Antineoplastic; D001391:Azo Compounds; D008727:Methotrexate
Protivoopukholevaia aktivnost' antibiotika 1719 iz gruppy diazosoedineniĭ.